WELLESLEY HILLS, Mass., Oct. 4 /PRNewswire-FirstCall/ -- MacroChem’s President and CEO, Robert DeLuccia, will host an Open House Presentation at the 15th Anniversary BioPartnering Europe Conference on Monday, October 8th from 10:00 AM - 12:30 PM GMT, in the Fleming Room at the Queen Elizabeth II Conference Centre in London, England. Mr. DeLuccia will join other leading biopharmaceutical and diagnostic companies from Europe, North America, and the rest of the world to host two-and-a-half- hour interactive multimedia sessions on science and technology, partnering strategies, developmental programs, commercialization plans, product opportunities, and manufacturing capabilities. Mr. DeLuccia will also present an overview of MacroChem’s progress and future business strategy in the Henry Moore Room East at 3:45 PM GMT.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of proprietary product candidates is based on our drug delivery technologies: SEPA(R), MacroDerm(TM) and DermaPass(TM). Our lead product candidate is EcoNail(R), a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. In addition to EcoNail and Opterone, our pipeline of early-stage product candidates is based on our SEPA, MacroDerm and DermaPass drug delivery technologies. For more information visit our website, http://www.macrochem.com. Recently, MacroChem announced it took a step to broaden its product portfolio by acquiring an exclusive option to license exclusive worldwide rights for drug uses of pexiganan, a small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI) from Genaera.
About BioPartnering Europe
BioPartnering Europe (BPE) was first held in London in 1993 as a partnership between the U.S. Commercial Service and Technology Vision Group LLC to bring about closer ties between American and European biotechnology companies. From the beginning, BPE has attracted the support of leading pharmaceutical, biotechnology, financial, and service companies who have all contributed to making this one of the leading independent partnering events in the world. BPE has a high rate of sponsor retention, which signals its prominent role in the annual conference calendar for many industry leaders. For more information, please visit the website, http://techvision.com/bpe/
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection, and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
bpatriacca@macrochem.comcberni@investorrelationsgroup.comjtriunfo@investorrelationsgroup.combdouglass@investorrelationsgroup.commheller@investorrelationsgroup.com
CONTACT: Bernard Patriacca, VP-CFO of MacroChem Corporation,
+1-781-489-7310, bpatriacca@macrochem.com; Investor Relations, Christine
Berni, cberni@investorrelationsgroup.com, or Joseph Triunfo,
jtriunfo@investorrelationsgroup.com, Media, Bill Douglass,
bdouglass@investorrelationsgroup.com, or Michaela Heller,
mheller@investorrelationsgroup.com, all of The Investor Relations Group,
Inc., for MacroChem Corporation, +1-212-825-3210
Web site: http://www.macrochem.com/
http://techvision.com/bpe//
